Nexalis Therapeutics Ltd

NEW
ASX:NX1 (Australia)  
A$ 0.018 (0%) Jun 26
At Loss
Market Cap:
A$ 4.55M ($ 3.21M)
Enterprise V:
A$ 4.86M ($ 3.42M)
Volume:
0
Avg Vol (2M):
261.47K
Trade In:

Business Description

Description
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt
0.59
Equity-to-Asset
-0.97
Debt-to-Equity
-0.63
Debt-to-EBITDA
-0.5
Piotroski F-Score
1/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate
14
3-Year EPS without NRI Growth Rate
10.1
3-Year FCF Growth Rate
28.6

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI
74.19
9-Day RSI
57.96
14-Day RSI
50.98
3-1 Month Momentum %
4.17
6-1 Month Momentum %
8.7
12-1 Month Momentum %
-37.04

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio
0.58
Quick Ratio
0.58
Cash Ratio
0.21

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio
-8.3
Shareholder Yield %
-25.51

Profitability Rank

Name Current Vs Industry Vs History
ROA %
-144.64
ROIC %
-1364.34
3-Year ROIIC %
-196.97

GF Value Rank

Name Current Vs Industry Vs History
EV-to-EBIT
-3.29
EV-to-EBITDA
-3.29
EV-to-FCF
-4.05
Earnings Yield (Greenblatt) %
-30.44
FCF Yield %
-19.5

GF Valueâ„¢

Nexalis Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Nexalis Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price (A$)
No Event Data

Press Release

Subject Date
No Press Release

Articles on Nexalis Therapeutics Ltd

No articles.